Sunesis Pharmaceuticals Inc (NASDAQ:SNSS): The company provided an update at the American Society of Hematology (ASH) 2018 meeting in December on its ongoing dose-escalation study of vecabrutinib for B-cell malignancies. Four new patients have been enrolled in the past month and the 50 mg cohort is now overenrolled. Safety data is only needed from a single patient, so barring any issues, the trial should progress to 100mg soon, where we may see the first signs of efficacy.
Signs of forward progress
The dosing study has struggled to progress past the 50mg cohort with delays due to a cohort expansion and patients that progressed before safety could be evaluated. However, following these most recent results it may soon be in the rear view. Enrolment appears to progressing steadily across the eight open clinical sites, and there are four patients on the drug after the enrolment, including two new patients in the 50mg cohort (although only one is needed to progress).
To read the entire report Please click on the pdf File Below..
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.